Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin
Completed · Phase 4
Conditions studied: Thrombocytopenia, Thrombosis
In brief
The purpose of this study is to evaluate the safe and effective dose of Argatroban for prophylaxis and/or treatment of thrombosis in pediatric patients with current or previous diagnosis of heparin-induced thrombocytopenia (HIT) and thrombosis syndrome (HITTS), or who in the opinion of the investigator require alternative anticoagulation due to an underlying condition.
Key facts
- Study ID
- NCT00039858
- Run by
- Encysive Pharmaceuticals
- People needed
- 24
- Starts
- 2003-09-01
- Expected to finish
- 2006-03-01
- Last updated by the study team
- 2007-01-11
Who can join
Age: any, up to 16. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Mattel Children's Hospital at UCLA — Los Angeles, California, United States
- Children's Hospital of Orange County — Orange, California, United States
- Rush University Medical Center — Chicago, Illinois, United States
- University of Chicago Children's Hospital — Chicago, Illinois, United States
- Children's Hospital of Illinois — Peoria, Illinois, United States
- Kosair Children's Hospital, University of Louisville — Louisville, Kentucky, United States
- Children's Hospital of Boston — Boston, Massachusetts, United States
- Michigan Congenital Heart Center — Ann Arbor, Michigan, United States
- Rainbow Babies at Children's Hospital — Cleveland, Ohio, United States
- Oregon Health & Science University — Portland, Oregon, United States
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States
- Primary Children's Medical Center — Salt Lake City, Utah, United States
- Children's Hospital and Regional Medical Center — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.